VKTX - Viking Therapeutics, Inc. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg · closes rebased to 100 at each year's first session
Ticker Details
Viking Therapeutics, Inc.
Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.
IPO Date: April 29, 2015
Sector: Healthcare
Industry: Biotech
Market Cap: $3.63B
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.57 | 3.76%
Avg Daily Range (30 D): $1.24 | 3.75%
Avg Daily Range (90 D): $1.06 | 3.11%
Institutional Daily Volume
Avg Daily Volume: 1.92M
Avg Daily Volume (30 D): 5.95M
Avg Daily Volume (90 D): 3.33M
Trade Size
Avg Trade Size (Sh.): 111
Avg Trade Size (Sh.) (30 D): 104
Avg Trade Size (Sh.) (90 D): 87
Institutional Trades
Total Institutional Trades: 6,776
Avg Institutional Trade: $2.43M
Avg Institutional Trade (30 D): $2.17M
Avg Institutional Trade (90 D): $2.73M
Avg Institutional Trade Volume: .08M
Avg Institutional Trades (Per Day): 4
Market Closing Trades
Avg Closing Trade: $6.61M
Avg Closing Trade (30 D): $10.85M
Avg Closing Trade (90 D): $9.5M
Avg Closing Volume: 249.17K
 
News
Oct 8, 2026 @ 11:31 AM
LLY Stock Down 2% in 3 Months: Is the Dip a Buying...
Source: Na
Oct 7, 2026 @ 3:17 PM
VKTX Advances Obesity Program With New Oral Mainte...
Source: Na
Oct 5, 2026 @ 8:20 PM
Eli Lilly Has Been a Growth Beast, but This Is the...
Source: David Jagielski, Cpa
Oct 5, 2026 @ 12:24 PM
Here Are My Top 4 Stocks to Buy in October
Source: James Brumley
Oct 2, 2026 @ 10:15 AM
Prediction: This Stock Could Double Over the Next ...
Source: Lee Samaha
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $-4.67 $-1.1 $-1.37
Diluted EPS $-4.67 $-1.1 $-1.37
Revenue $M $M $M
Gross Profit
Net Income / Loss $-534.8M $-128.02M $-158.33M
Operating Income / Loss $-560.02M $-132.6M $-164.13M
Cost of Revenue
Net Cash Flow $92.06M
PE Ratio